Ligand Pharmaceuticals: Buy This Strong Growing Pharma And Get A Stake In Dozens Of Therapies

This is my eighth Ligand (NASDAQ: LGND ) article, following my most recent 07/2024's "Ligand Pharmaceuticals: Solid Performer Performing Solidly" (" Solid "). In Solid, I rated Ligand as a "Buy". In the interim, it has risen a modest ~9.6%. InWriting under the pseudonym "out of ignorance", I very much regard investing as a learning process. Investing failures are tuition paid. Investing successes enter the trove of lessons learned. In my Seeking Alpha articles I share my experience from decades of investing ...